Antiparkinsonian medications might improve mood disorders through the relief of motor manifestations and disability, the enhancement of feelings of disease mastery, or the restoration of ...

In a recent study by Paolo Barone and colleagues, a dopamine agonist, pramipexole, improved depressive symptoms after 12 weeks in European and South African patients undergoing antiparkinsonian ...

L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated patients develop disabling motor response complications. Alternatives to L-dopa for initial treatment of ...

antiparkinsonian drugs like biperiden and amantadine, drugs used in the treatment of depression like amitriptyline due to the additional anticholinergic effect of the drugs. • Gastrointestinal ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...